TY - JOUR
T1 - Enterococcus faecalis infective endocarditis
T2 - focus on clinical aspects.
AU - Dahl, Anders
AU - Bruun, Niels Eske
PY - 2013/9
Y1 - 2013/9
N2 - Enterococcus faecalis infective endocarditis (IE) is a disease of increasing importance, with more patients infected, increasing frequency of health-care associated infections and increasing incidence of antimicrobial resistances. The typical clinical presentation is a subacute course with fever, malaise and generalized aches, difficult to distinguish from other more common diseases. Of paramount importance is transthoracic- and transesophageal-echocardiography to establish the diagnosis. At the moment, the predominant strategies recommend ampicillin in combination with either gentamicin or ceftriaxone. E. faecalis infective endocarditis continues to be a very serious disease with considerable percentages of high-level gentamicin resistant strains and in-hospital mortality around 20%. Strategies to prevent E. faecalis IE, improve diagnostics, optimize treatment and reduce morbidity will be necessary to improve the overall prognosis.
AB - Enterococcus faecalis infective endocarditis (IE) is a disease of increasing importance, with more patients infected, increasing frequency of health-care associated infections and increasing incidence of antimicrobial resistances. The typical clinical presentation is a subacute course with fever, malaise and generalized aches, difficult to distinguish from other more common diseases. Of paramount importance is transthoracic- and transesophageal-echocardiography to establish the diagnosis. At the moment, the predominant strategies recommend ampicillin in combination with either gentamicin or ceftriaxone. E. faecalis infective endocarditis continues to be a very serious disease with considerable percentages of high-level gentamicin resistant strains and in-hospital mortality around 20%. Strategies to prevent E. faecalis IE, improve diagnostics, optimize treatment and reduce morbidity will be necessary to improve the overall prognosis.
UR - http://www.scopus.com/inward/record.url?scp=84898909246&partnerID=8YFLogxK
U2 - 10.1586/14779072.2013.832482
DO - 10.1586/14779072.2013.832482
M3 - Review
C2 - 24073680
AN - SCOPUS:84898909246
SN - 1477-9072
VL - 11
SP - 1247
EP - 1257
JO - Expert review of cardiovascular therapy
JF - Expert review of cardiovascular therapy
IS - 9
ER -